The rakish profile of the concept may suggest a fastback sedan at first blush, but in reality the images hide something closer to a fastback crossover with some generous ground clearance and a very blunt nose. It’s not …
See Original Article

The treatment, a combination of casirivimab with imdevimab, lowered the risk of hospitalization or death in high-risk, non-hospitalized patients by 70% compared with placebo, the companies said. The drug combo …
See Original Article

(Adds details). ZURICH, March 23 (Reuters) – Novartis’ experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday. The therapy, which …
See Original Article

PD-1/L1 inhibitors have had a relatively low success rate against cancers that affect the digestive system. But Merck & Co.’s can now tout a first-in-class approval for one disease type—though its archrival Bristol Myers Squibb isn’t so far behind.
See Original Article

Adds share movement, detail on deal, liquidity, background. March 23 (Reuters) – British Airways owner IAG ICAG.L said on Tuesday it had secured a $1.76 billion credit facility from a group of banks that would be available to its coronavirus-hit airlines Aer …
See Original Article